


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:43Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406252" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406252</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="a756743216" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">mp</journal-id><journal-title-group><journal-title>Molecular Pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><self-uri>pubs.acs.org/molecularpharmaceutics</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406252</article-id><article-id pub-id-type="pmcid-ver">PMC12406252.1</article-id><article-id pub-id-type="pmcaid">12406252</article-id><article-id pub-id-type="pmcaiid">12406252</article-id><article-id pub-id-type="pmid">40833925</article-id><article-id pub-id-type="doi">10.1021/acs.molpharmaceut.5c00572</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development
of a Theranostic Agent for Bone Metastases:
Integration of Nuclear Medicine Imaging and Boron Neutron Capture
Therapy (BNCT)</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7615663</contrib-id><name name-style="western"><surname>Tamamura</surname><given-names initials="K">Kisa</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7615659</contrib-id><name name-style="western"><surname>Akita</surname><given-names initials="Y">Yuito</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3316174</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5071-7574</contrib-id><name name-style="western"><surname>Mishiro</surname><given-names initials="K">Kenji</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6052819</contrib-id><name name-style="western"><surname>Munekane</surname><given-names initials="M">Masayuki</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1745346</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8141-1212</contrib-id><name name-style="western"><surname>Fuchigami</surname><given-names initials="T">Takeshi</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7615656</contrib-id><name name-style="western"><surname>Fujikawa</surname><given-names initials="Y">Yoshiki</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6389164</contrib-id><name name-style="western"><surname>Wakabayashi</surname><given-names initials="H">Hiroshi</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7775491</contrib-id><name name-style="western"><surname>Ikoma</surname><given-names initials="F">Fuko</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3852271</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6188-4039</contrib-id><name name-style="western"><surname>Hu</surname><given-names initials="X">Xiaojun</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5649528</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5007-5279</contrib-id><name name-style="western"><surname>Kawabata</surname><given-names initials="S">Shinji</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6085570</contrib-id><name name-style="western"><surname>Kinuya</surname><given-names initials="S">Seigo</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath12" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6367141</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5421-9417</contrib-id><name name-style="western"><surname>Suzuki</surname><given-names initials="M">Minoru</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath13" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1940645</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1691-7302</contrib-id><name name-style="western"><surname>Ogawa</surname><given-names initials="K">Kazuma</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>1</label>
<institution content-type="dept">Graduate
School of Medical Sciences</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">12858</institution-id><institution>Kanazawa University</institution></institution-wrap>, <city>Kanazawa</city>, <state>Ishikawa</state>
<postal-code>920-1192</postal-code>, <country country="JP">Japan</country>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="dept">Department
of Neurosurgery</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">13010</institution-id><institution>Osaka Medical and Pharmaceutical
University</institution></institution-wrap>, <city>Takatsuki</city>, <state>Osaka</state>
<postal-code>569-8686</postal-code>, <country country="JP">Japan</country>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="dept">Department
of Nuclear Medicine</institution>, <institution>Kanazawa University
Hospital, Kanazawa University</institution>, <addr-line>Takara-machi 13-1</addr-line>, <city>Kanazawa</city>, <state>Ishikawa</state>
<postal-code>920-8641</postal-code>, <country country="JP">Japan</country>
</aff><aff id="aff4">
<label>4</label>
<institution content-type="dept">Center for
Molecular Recognition and Biosensing, School of Life Sciences</institution>, <institution>Shanghai University</institution>, <city>Shanghai</city>
<postal-code>200444</postal-code>, <country country="CN">China</country>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="dept">Institute
for Integrated Radiation and Nuclear Science</institution>, <institution>Kyoto University</institution>, <city>Kumatori</city>, <state>Osaka</state>
<postal-code>590-0494</postal-code>, <country country="JP">Japan</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>kogawa@p.kanazawa-u.ac.jp</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>01</day><month>9</month><year>2025</year></pub-date><volume>22</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>5546</fpage><lpage>5554</lpage><history><date date-type="received"><day>21</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>12</day><month>8</month><year>2025</year></date><date date-type="online"><day>20</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-20"/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense" start_date="2025-08-20">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY-NC-ND 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="mp5c00572.pdf"/><abstract><p>Boron neutron capture therapy (BNCT) is one of the promising
cancer
treatment methods with <sup>10</sup>B-labeled compounds and neutron
irradiation. The <sup>10</sup>B&#173;(n,&#945;)<sup>7</sup>Li reaction
produces a <sup>7</sup>Li nucleus and an &#945;-particle with high
linear energy transfer, which are responsible for the therapeutic
effects. We hypothesized that BNCT could effectively treat bone metastases
by selectively accumulating <sup>10</sup>B at metastatic lesion sites.
In this study, we designed, synthesized, and evaluated [<sup>nat/67</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> ([<sup>nat/67</sup>Ga]<bold>6</bold>), a compound integrating <italic toggle="yes">closo</italic>-dodecaborate for BNCT, a [<sup>nat/67</sup>Ga]&#173;Ga-DOTA
derivative for nuclear imaging, and D<sub>11</sub>, an aspartic acid
peptide, for bone targeting. [<sup>67</sup>Ga]<bold>6</bold> and its
precursor <bold>5</bold>, which lacks gallium coordination, showed
comparable biodistribution in normal mice, with high bone uptake and
minimal off-target accumulation. These results support the potential
of [<sup>nat/67/68</sup>Ga]<bold>6</bold> as an effective theranostic
agent for bone metastases.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="mp5c00572_0011.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="mp5c00572_0009.jpg"/></abstract><kwd-group><kwd>boron neutron capture therapy (BNCT)</kwd><kwd>theranostics</kwd><kwd>bone metastases</kwd><kwd>peptide</kwd><kwd>aspartic acid</kwd></kwd-group><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Naito Foundation</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100007428</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Japan Society for the Promotion of Science</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100001691</institution-id></institution-wrap></funding-source><award-id>21H02867</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>Kobayashi Foundation for Cancer Research</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100007533</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group id="fnd-4"><funding-source><institution-wrap><institution>NOVARTIS Foundation (Japan) for the Promotion of Science</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100011746</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mp5c00572</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mp5c00572</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>c82b477debd1e900969e5ef2eac43526933f6b2918f22512e3f81465aac56873</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Boron neutron capture therapy (BNCT) is
a promising cancer treatment
that relies on the selective uptake of boron-10 (<sup>10</sup>B) labeled
compounds into cancer cells, followed by neutron irradiation.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref2" ref-type="bibr"/>
</named-content> Upon exposure to thermal neutrons, <sup>10</sup>B undergoes a nuclear
reaction, <sup>10</sup>B&#173;(n, &#945;)<sup>7</sup>Li, producing an &#945;-particle
and a <sup>7</sup>Li nucleus. Both particles are characterized by
high linear energy transfer (LET) and relative biological effectiveness
(RBE), making them highly cytotoxic. With ranges of approximately
9 and 4 &#956;m, respectively, near or below the diameter of a single
cell, these particles enable the selective killing of cancer cells
while minimizing damage to surrounding normal tissues.<xref rid="ref3" ref-type="bibr"/> For BNCT to be effective, high and selective accumulation
of <sup>10</sup>B in the target cells is essential.<xref rid="ref4" ref-type="bibr"/>
</p><p>Bone, rich in growth factors, provides a favorable
environment
for cancer proliferation. Consequently, bone metastases frequently
occurred in patients with breast, prostate, and lung cancers.<named-content content-type="bibref-group">
<xref rid="ref5" ref-type="bibr"/>,<xref rid="ref6" ref-type="bibr"/>
</named-content> As bone metastases progress, complications such as fractures, pain,
and spinal cord compression arise, significantly diminishing patients&#8217;
quality of life. Current clinical treatments for bone metastases include
surgery, radiotherapy, hormone therapy, chemotherapy, and targeted
pharmaceuticals, such as zoledronic acid and denosumab, that interrupt
the &#8220;vicious cycle&#8221; of bone destruction.<xref rid="ref7" ref-type="bibr"/> However, these treatments primarily aim to prevent fractures
and alleviate pain, rather than eliminate metastases.<named-content content-type="bibref-group">
<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>
</named-content> Bone-seeking radiopharmaceuticals labeled with &#946;<sup>&#8211;</sup> emitting radionuclides, such as [<sup>89</sup>Sr]&#173;SrCl<sub>2</sub> (Metastron) and [<sup>153</sup>Sm]&#173;Sm-EDTMP (Quadramet), offer only
palliative relief. In contrast, [<sup>223</sup>Ra]&#173;RaCl<sub>2</sub> (Xofigo), an &#945;-emitter, not only relieves pain but also prolongs
overall survival and delays the onset of skeletal-related events in
castration resistant prostate cancer patients.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>&#8722;<xref rid="ref11" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref12" ref-type="bibr"/>
</named-content> Inspired by
the efficacy of [<sup>223</sup>Ra]&#173;RaCl<sub>2</sub>, we hypothesized
that BNCT&#58872;using bone-targeting <sup>10</sup>B-labeled compounds&#58872;could
be an effective treatment strategy for certain types of bone metastases.</p><p>We have developed various radiolabeled bone-seeking agents using
bisphosphonates<named-content content-type="bibref-group">
<xref rid="ref13" ref-type="bibr"/>&#8722;<xref rid="ref14" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref17" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref18" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref19" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref20" ref-type="bibr"/>
</named-content> and acidic oligopeptides<named-content content-type="bibref-group">
<xref rid="ref21" ref-type="bibr"/>&#8722;<xref rid="ref22" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr"/>
</named-content> as bone carriers. Our previous study demonstrated
that [<sup>67</sup>Ga]&#173;Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA)-D<sub>11</sub> exhibited excellent biodistribution as
a bone-imaging probe.<xref rid="ref21" ref-type="bibr"/> Additionally, radiolabeled
combination peptides, such as [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-c&#173;(RGDfK) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>a), [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-TATE (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>b), and [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-PSMA617 (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>c), also showed high bone uptake.<named-content content-type="bibref-group">
<xref rid="ref25" ref-type="bibr"/>&#8722;<xref rid="ref26" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref27" ref-type="bibr"/>
</named-content> These findings
indicate that D<sub>11</sub> retains bone affinity even when conjugated
to moderately sized molecules. We also developed <italic toggle="yes">closo</italic>-dodecaborate-(Ga-DOTA)-c&#173;(RGDfK) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>d), a probe with a structure compatible for
both BNCT and PET diagnostics.<xref rid="ref28" ref-type="bibr"/> It features
a <italic toggle="yes">closo</italic>-dodecaborate ([B<sub>12</sub>H<sub>12</sub>]<sup>2&#8211;</sup>) boron cluster with multiple <sup>10</sup>B
molecules, a [<sup>68</sup>Ga]&#173;Ga-DOTA derivative as a stable <sup>68</sup>Ga (<italic toggle="yes">T</italic>
<sub>1/2</sub>: 68 min) complex for
PET imaging, and an arginine-glycine-aspartic acid (RGD) peptide for
tumor targeting. This probe showed promising potential as a theranostic
agent.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Structures of (a) [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-c&#173;(RGDfK),
(b) [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-TATE, (c) [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-PSMA617, and (d) <italic toggle="yes">closo</italic>-dodecaborate-[<sup>67</sup>Ga]&#173;Ga-DOTA-c&#173;(RGDfK).</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="mp5c00572_0001.jpg"/></fig><p>In this study, we hypothesized that [<sup>nat/68</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub>, which contains <italic toggle="yes">closo</italic>-dodecaborate for BNCT, [<sup>nat/68</sup>Ga]&#173;Ga-DOTA
complex for PET imaging, and D<sub>11</sub> for bone affinity, could
serve as a theranostic agent for patients with bone metastases (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). Although our ultimate
goal was to develop a <sup>68</sup>Ga-labeled PET agent, <sup>67</sup>Ga (<italic toggle="yes">T</italic>
<sub>1/2</sub>: 3.3 days) was used instead,
owing to its easier handling during synthesis and evaluation, and
synthesized [<sup>67</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub>.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Concept of the drug design in this study;
a structure of [<sup>nat/68</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> ([<sup>nat/68</sup>Ga]<bold>6</bold>).</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="mp5c00572_0002.jpg"/></fig></sec><sec id="sec2"><title>Materials and Methods</title><sec id="sec2.1"><title>Materials</title><p>
<sup>1</sup>H nuclear magnetic resonance
(NMR) spectra were recorded on JEOL JNM-ECS400 (JEOL Ltd., Tokyo,
Japan) operating at 400 MHz. Chemical shifts for <sup>1</sup>H NMR
were reported in ppm units relative to residual solvent signal (2.50
ppm in DMSO-<italic toggle="yes">d</italic>
<sub>
<italic toggle="yes">6</italic>
</sub>). Electrospray
ionization mass spectra (ESI-MS) were obtained using an LCMS-9030
(Shimadzu Co., Kyoto, Japan). [<sup>67</sup>Ga]&#173;Ga-citrate (Nihon Medi-Physics
Co., Ltd., Tokyo, Japan) was converted to [<sup>67</sup>Ga]&#173;GaCl<sub>3</sub> using Sep-Pak Silica Plus Light Cartridge (Waters Co., Ltd.,
Milford, MA, USA) as described in previous reports.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>,<xref rid="ref30" ref-type="bibr"/>
</named-content> Sodium dodecahydrododecaborate was purchased from Katchem. Ltd.
(Prague, Czech). 2-Chlorotrityl chloride resin (Watanabe Chemical
Industries, Ltd., Hiroshima, Japan), Fmoc-<sc>l</sc>-Asp&#173;(O<italic toggle="yes">t</italic>Bu)-OH and Fmoc-<sc>l</sc>-Lys&#173;(Boc)-OH (AmBeed, Arlington
Heights, IL, USA) were used for the peptide synthesis. Cyclen was
obtained from BLD pharmatech Ltd. (Shanghai, China). <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-Diisopropylethylamine (DIPEA) was obtained from
Nacalai Tesque (Kyoto, Japan). 1,3-Diisopropylcarbodiimide (DIPCDI)
and 1-hydroxybenzotriazole hydrate (HOBt) were obtained from Kokusan
Chemical Co., Ltd. (Tokyo, Japan). Other reagents were of reagent
grade and used as received.</p></sec><sec id="sec2.2"><title>Preparation of [<sup>nat/67</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> ([<sup>nat/67</sup>Ga]<bold>6</bold>)</title><p>Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> (<bold>6</bold>) and [<sup>67</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> ([<sup>67</sup>Ga]<bold>6</bold>) were synthesized following the procedure shown in <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>.</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthetic Scheme
of Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> (<bold>6</bold>) or [<sup>67</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> ([<sup>67</sup>Ga]<bold>6</bold>)&#173;<xref rid="sch1-fn1" ref-type="fn"/>
</title></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="mp5c00572_0008.jpg"/><p>
<fn id="sch1-fn1"><label>a</label><p>Reagents: (a) EDCI&#183;HCl,
CH<sub>2</sub>Cl<sub>2</sub>, rt, (b) TEA, DMF, rt, (c) TFA, H<sub>2</sub>O, TIS, rt, (d) TEA, DMF, rt, (e) Ga&#173;(NO<sub>3</sub>)<sub>3</sub>, 3 M ammonium acetate buffer (pH 5.0), 40 &#176;C or [<sup>67</sup>Ga]&#173;GaCl<sub>3</sub>, 3 M ammonium acetate buffer (pH 5.0), 80 &#176;C</p></fn>
</p></fig></sec><sec id="sec2.3"><title>Bis&#173;(2,5-dioxopyrrolidin-1-yl) terephthalate (<bold>1</bold>)</title><p>Terephthalic acid (0.5 g, 3.0 mmol), <italic toggle="yes">N</italic>-hydroxysuccinimide
(0.8 g, 7.3 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)&#173;carbodiimide
hydrochloride (EDCI&#183;HCl) (1.4 g, 7.5 mmol) were dissolved in
30 mL of dichloromethane. After 3 h stirring of the solution at room
temperature, the solution was concentrated <italic toggle="yes">in vacuo</italic> and the residue was purified by silica gel column chromatography
eluted with a gradient mobile phase of hexane/ethyl acetate, 50/50
to 0/100 to afford <bold>1</bold> (0.3 g, 30%) as a colorless powder.</p><p>
<sup>1</sup>H NMR (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>
<italic toggle="yes">6</italic>
</sub>) &#948; ppm 2.91 (s, 8H), 8.31 (s, 4H).</p></sec><sec id="sec2.4"><title>Compound <bold>3</bold>
</title><p>To a solution of dodecaborate
derivative <bold>2</bold> (20 mg, 41 &#956;mol), which was synthesized
according to a previous report,<xref rid="ref28" ref-type="bibr"/> in 3
mL of <italic toggle="yes">N,N</italic>-dimethylformamide (DMF), <bold>1</bold> (74 mg, 0.21 mmol) and triethylamine (TEA) (23 &#956;L, 0.16 mmol)
were added. After the mixture was stirred for 18 h at room temperature,
the solution was concentrated <italic toggle="yes">in vacuo</italic>. The residue
was purified by silica gel column chromatography eluted with a gradient
mobile phase of ethyl acetate/acetonitrile, 100/0 to 0/100 to afford <bold>3</bold> (24 mg, 80%) as a colorless powder.</p><p>HRMS (ESI<sup>&#8211;</sup>) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M-H]<sup>&#8722;</sup> calcd for C<sub>16</sub>H<sub>27</sub>B<sub>12</sub>N<sub>2</sub>O<sub>7</sub>: 489.3013; found, 489.3032.</p></sec><sec id="sec2.5"><title>DOTA-KD<sub>11</sub> (<bold>4</bold>)</title><p>Compound <bold>4</bold> was manually prepared using the conventional Fmoc-based
solid-phase synthesis method. Namely, after binding Fmoc-<sc>l</sc>-Asp&#173;(O<italic toggle="yes">t</italic>Bu)-OH to 2-chlorotrityl-chloride resin,
the target peptide was synthesized using Fmoc-<sc>l</sc>-Asp&#173;(O<italic toggle="yes">t</italic>Bu)-OH, Fmoc-<sc>l</sc>-Lys&#173;(Boc)-OH, and DOTA-tris&#173;(<italic toggle="yes">t</italic>Bu ester) according to a previously reported procedure.<xref rid="ref31" ref-type="bibr"/> The peptide was cleaved from the resin and the
protecting groups were removed using a mixture of 95% trifluoroacetic
acid (TFA), 2.5% water, and 2.5% triisopropylsilane (TIS). The crude
peptide was purified by reversed-phase (RP)-HPLC on a Cosmosil 5C<sub>18</sub>-AR-II column (20 &#215; 250 mm) at a flow rate of 12 mL/min,
employing a gradient elution from 5% to 20% methanol in water containing
0.1% TFA for 20 min. The solvent was removed by lyophilization to
yield <bold>4</bold> (14.2 mg, 7.9%) as a colorless powder.</p><p>HRMS (ESI<sup>+</sup>) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M+2H]<sup>2+</sup> calcd for C<sub>66</sub>H<sub>95</sub>N<sub>17</sub>O<sub>42</sub>: 899.7983; found, 899.8000.</p></sec><sec id="sec2.6"><title>DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> (<bold>5</bold>)</title><p>Compound <bold>3</bold> (6.2 mg, 8.4 &#956;mol), <bold>4</bold> (5.0 mg, 2.8 &#956;mol), and TEA (80 &#956;L, 0.58 mmol)
were dissolved in 0.4 mL of DMF. After 3 h stirring at room temperature,
the solution was concentrated <italic toggle="yes">in vacuo</italic> and purified
by RP-HPLC on a Cosmosil 5C<sub>18</sub>-AR-II column (10 &#215; 150
mm) at a flow rate of 4 mL/min, employing a gradient elution from
15% to 45% methanol in water containing 0.1% TFA for 20 min. The solvent
was removed by lyophilization to yield <bold>5</bold> (2.3 mg, 38%)
as a colorless powder.</p><p>HRMS (ESI<sup>&#8211;</sup>) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M-2H]<sup>2&#8211;</sup> calcd for
C<sub>78</sub>H<sub>118</sub>B<sub>12</sub>N<sub>18</sub>O<sub>46</sub>: 1086.4324; found, 1086.4357.</p></sec><sec id="sec2.7"><title>Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> (<bold>6</bold>)</title><p>Compound <bold>5</bold> (1.6 mg,
0.7 &#956;mol) was dissolved in 3 M ammonium acetate buffer (pH 5.0),
and Ga&#173;(NO<sub>3</sub>)<sub>3</sub> (1.9 &#956;g, 7.4 &#956;mol)
was added to the solution. After 2 h stirring at 40 &#176;C, the mixture
was purified by RP-HPLC on a Cosmosil 5C<sub>18</sub>-AR-II column
(4.6 &#215; 150 mm) at a flow rate of 1 mL/min, employing a gradient
elution from 15% to 55% methanol in water containing 0.1% TFA for
20 min. The solvent was removed by lyophilization to yield <bold>6</bold> (0.45 mg, 27%) as a colorless powder.</p><p>MS (ESI<sup>&#8211;</sup>) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>: [M]<sup>2&#8211;</sup> calcd
for C<sub>78</sub>H<sub>116</sub>B<sub>12</sub>GaN<sub>18</sub>O<sub>46</sub>: 1119.8874; found, 1119.8863.</p></sec><sec id="sec2.8"><title>[<sup>67</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> ([<sup>67</sup>Ga]<bold>6</bold>)</title><p>Compound <bold>5</bold> (41 &#956;g, 19 nmol) was dissolved in a mixed solution
consisting of 40 &#956;L of 3 M ammonium acetate buffer (pH 5.0)
and 40 &#956;L of [<sup>67</sup>Ga]&#173;GaCl<sub>3</sub> (1.1 MBq) in
0.1 M aqueous HCl. After reaction at 80 &#176;C for 15 min, [<sup>67</sup>Ga]<bold>6</bold> was purified and analyzed by RP-HPLC on
a Cosmosil 5C<sub>18</sub>-AR-II column (4.6 &#215; 150 mm) at the
same conditions as those used for <bold>6</bold>.</p></sec><sec id="sec2.9"><title>Hydroxyapatite Binding Assay</title><p>A hydroxyapatite-binding
assay was conducted according to previously reported procedures.<xref rid="ref18" ref-type="bibr"/> In brief, hydroxyapatite beads (Bio-Gel; Bio-Rad,
Hercules, CA, USA) were suspended in Tris/HCl-buffered saline (50
mM, pH 7.4) at concentrations of 1, 2.5, 10, and 25 mg/mL. Solutions
of [<sup>67</sup>Ga]<bold>6</bold> were prepared at a final ligand
concentration of 19.5 &#956;M by adding <bold>5</bold>, instead of <bold>6</bold>. Each [<sup>67</sup>Ga]<bold>6</bold> solution (200 &#956;L)
was mixed with the hydroxyapatite suspension (200 &#956;L) and gently
shaken at room temperature for 1 h. The mixtures were centrifuged
at 10,000<italic toggle="yes">g</italic> for 5 min, and the radioactivity of the
supernatants was measured using an auto well gamma counter (ARC-8001,
ALOKA Co., Ltd., Tokyo, Japan). Control experiments were performed
in the same manner without hydroxyapatite beads. The hydroxyapatite
binding ratios were calculated as<disp-formula id="ueq1"><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00572_m001.jpg"/><mml:math id="d1e1007" display="block"><mml:mi>Hydroxyapatite</mml:mi><mml:mspace width="0.25em"/><mml:mi>binding</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>radioactivity</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>sample</mml:mi><mml:mspace width="0.25em"/><mml:mi>supernatant</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>radioactivity</mml:mi><mml:mspace width="0.25em"/><mml:mi>of</mml:mi><mml:mspace width="0.25em"/><mml:mi>control</mml:mi><mml:mspace width="0.25em"/><mml:mi>supernatant</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives></disp-formula>
</p></sec><sec id="sec2.10"><title>
<italic toggle="yes">In Vitro</italic> Stability Experiment</title><p>The
stability experiment of [<sup>67</sup>Ga]<bold>6</bold> in murine
plasma was evaluated with slight modifications to previous reported
methods.<named-content content-type="bibref-group">
<xref rid="ref32" ref-type="bibr"/>,<xref rid="ref33" ref-type="bibr"/>
</named-content> Briefly, [<sup>67</sup>Ga]<bold>6</bold> was mixed with murine plasma at a 1:9 ratio (v/v) and incubated
at 37 &#176;C for 10 min and 1 h. An equal volume of ice-cold acetonitrile
with 0.1% trichloroacetic acid was added, and the mixture was kept
on ice for 15 min. After centrifugation at 1,700<italic toggle="yes">g</italic> for 15 min at 4 &#176;C, the supernatant was filtered through a
0.45-&#956;m membrane filter. The filtrates were subsequently subjected
to RP-HPLC analysis, as described above, to determine the radiochemical
purity.</p></sec><sec id="sec2.11"><title>Animals</title><p>All animal experiments were performed in compliance
with the Guidelines for the Care and Use of Laboratory Animals of
Kanazawa University and were approved by the Committee on Animal Experimentation
of Kanazawa University (AP20&#8211;012 and AP22&#8211;028&#8211;01).
The animals were maintained under controlled conditions (23 &#176;C,
12 h light/dark cycle) with free access to food and water.</p></sec><sec id="sec2.12"><title>A Biodistribution Experiment of [<sup>67</sup>Ga]<bold>6</bold>
</title><p>A biodistribution experiment was conducted after an intravenous
injection of [<sup>67</sup>Ga]<bold>6</bold> solution diluted in saline
(37 kBq/100 &#956;L) to 6-week-old male ddY mice (27&#8211;32 g,
Japan SLC, Inc., Hamamatsu, Japan). Four mice at each time point were
sacrificed at 10 min, 1 h, and 3 h postinjection. Tissues of interest
were excised and weighed. The whole left femur was taken as a representative
bone sample, and its radioactivity was measured using an auto well
gamma counter (ARC-8001, ALOKA Co., Ltd.). The counts were corrected
for background radiation and physical decay during measurement.</p><p>To investigate the effect of ligand amount on the biodistribution
of [<sup>67</sup>Ga]<bold>6</bold>, 515 &#956;g (0.4 mmol) or 2.06
mg (1.6 mmol) of (Asp)<sub>11</sub> was administered just before [<sup>67</sup>Ga]<bold>6</bold> injection, and the biodistribution at 1
h postinjection was evaluated using the same method as described above.
Ideally, <bold>6</bold> should be used as the ligand; however, due
to synthetic limitations, (Asp)<sub>11</sub>, which is the moiety
responsible for the target binding of <bold>6</bold>, was used instead.</p></sec><sec id="sec2.13"><title>Analysis of Urine Samples</title><p>Urine samples were collected
from the bladder of 6-week-old male ddY mice (27&#8211;32 g, Japan
SLC, Inc.) under anesthesia at 1 h after intravenous injection of
[<sup>67</sup>Ga]<bold>6</bold> (0.72 MBq/100 &#956;L). The urine
samples were filtered through a 0.45-&#956;m filter followed by RP-HPLC
analysis with a Cosmosil 5C<sub>18</sub>-AR-II column (4.6 &#215;
150 mm) at a flow rate of 1 mL/min with a gradient mobile phase of
12% to 35% methanol in water with 0.1% TFA for 20 min.</p></sec><sec id="sec2.14"><title>Determination of Boron Concentration in a Biodistribution Experiment
of <bold>5</bold>
</title><p>A biodistribution experiment was performed
after an intravenous administration of 418.9 &#956;g (25 &#956;g
as boron) of DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> (<bold>5</bold>) solution diluted in saline (100 &#956;L)
to 6-week-old male ddY mice (27&#8211;32 g, Japan SLC, Inc.). The
injected dose of 419 &#956;g corresponds to approximately 14 mg/kg
(833 &#956;g/kg as boron), assuming an average mouse body weight
of about 30 g. Mice were sacrificed at 1 h postinjection. Tissues
of interest were removed and weighed. Complete right and left femurs
were isolated as representative bone samples. Each tissue was ashed
with 500 &#956;L of 60% nitric acid at 110 &#176;C for 48 h, and
500 &#956;L of Indium standard solution (In 1000) (Fujifilm Wako
Pure Chemicals Co., Ltd., Osaka, Japan) diluted to 200 ppb was added
as an internal standard. After the solution was diluted with water
to 5 mL, the solution was diluted with 20 ppb of indium standard solution
in 6% nitric acid to 20 mL. The boron concentration in the solution
was determined with an Inductively Coupled Plasma Optical Emission
Spectroscopy (ICP-OES) (iCAP Pro XP Duo, Thermo Fisher Scientific,
Waltham, MA, USA). ICP standard solution B (Kanto Chemical Co., Ltd.,
Tokyo, Japan) was used for the calibration curve. The boron concentration
in each organ was expressed as a percentage of the injected boron
dose in <bold>5</bold> per tissue weight (%ID/g).</p></sec><sec id="sec2.15"><title>SPECT/CT Imaging and Data Reconstruction</title><p>SPECT/CT imaging
of [<sup>67</sup>Ga]<bold>6</bold> in a normal mouse was carried out
using a small animal SPECT system (VECTor/CT, MIlabs, Houten, The
Netherlands). SPECT acquisition was conducted 3 h after intravenous
injection of [<sup>67</sup>Ga]<bold>6</bold> (approximately 3.9 MBq).
Data acquisition, reconstruction, and imaging analysis were performed
according to a previous report.<xref rid="ref34" ref-type="bibr"/>
</p></sec><sec id="sec2.16"><title>Statistical Evaluation</title><p>The results of biodistribution
experiments of [<sup>67</sup>Ga]<bold>6</bold> and <bold>5</bold> were
compared using unpaired Student&#8217;s <italic toggle="yes">t</italic> test.
A <italic toggle="yes">p</italic>-value of less than 0.05 was considered statistically
significant.</p></sec></sec><sec id="sec3"><title>Results and Discussion</title><sec id="sec3.1"><title>Probe Design and Synthesis</title><p>In probe design, although
it was possible to introduce radioiodine into the boron cluster instead
of a [<sup>67/68</sup>Ga]&#173;Ga-DOTA complex, we selected the Ga-DOTA
strategy for the following reasons: (1) The product labeled with a
[<sup>67/68</sup>Ga]&#173;Ga-DOTA complex under optimized conditions can
often be used without purification, which simplifies the procedure
and makes it more suitable for clinical use compared with radioiodinated
compounds. (2) Radioiodination of dodecaborate structures could generate
isomeric mixtures,<xref rid="ref28" ref-type="bibr"/> complicating the synthesis
and purification of a single defined compound, although introducing
an alternative site for radioiodination may help avoid this issue.<xref rid="ref35" ref-type="bibr"/> (3) Incorporation of a Ga-DOTA complex enhances
the water solubility of the compound, thereby reducing nonspecific
accumulation and off-target radioactivity.</p><p>Precursor <bold>5</bold>, nonradioactive gallium complex <bold>6</bold>, and <sup>67</sup>Ga complex [<sup>67</sup>Ga]<bold>6</bold> were synthesized as shown
in <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>. Initial
attempts utilized <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#8217;-disuccinimidyl
glutarate as a linker between 2-(2-methoxyethoxy)&#173;ethan-1-amino-<italic toggle="yes">closo</italic>-dodecaborate and the &#949;-amino group of lysine
in <bold>4</bold>. However, this resulted in a highly hydrophilic
precursor with low UV absorption, which was undesirable for HPLC analysis
and purification. To address this, we employed <bold>1</bold>, a bis-NHS
ester with a benzene ring, as the linker. Precursor <bold>5</bold> was obtained in a 3% overall yield and high purity (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00572/suppl_file/mp5c00572_si_001.pdf" ext-link-type="uri">Figure. S1</ext-link>) after RP-HPLC purification. [<sup>67</sup>Ga]<bold>6</bold> was synthesized with a radiochemical yield
of 44.0 &#177; 1.2% and radiochemical purity exceeding 95%. The identity
of [<sup>67</sup>Ga]<bold>6</bold> was confirmed by comparing its
retention time with that of <bold>6</bold>. Chromatograms of [<sup>67</sup>Ga]<bold>6</bold> and <bold>6</bold> analyzed by RP-HPLC
are shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>RP-HPLC chromatograms of (a) [<sup>67</sup>Ga]&#173;Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> ([<sup>67</sup>Ga]<bold>6</bold>) and (b) Ga-DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> (<bold>6</bold>). HPLC conditions: a flow rate of 1.0 mL/min
with a gradient elution from 15% to 55% methanol in water containing
0.1% TFA for 20 min.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="mp5c00572_0003.jpg"/></fig></sec><sec id="sec3.2"><title>Hydroxyapatite Binding Assay</title><p>The hydroxyapatite binding
affinity of [<sup>67</sup>Ga]<bold>6</bold> is shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>. The binding rate increased
in a concentration-dependent manner, indicating strong affinity for
hydroxyapatite.</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Hydroxyapatite binding assay. Binding ratios of [<sup>67</sup>Ga]<bold>6</bold> to hydroxyapatite beads. Data are expressed
as the mean
&#177; SD for three or four samples.</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="mp5c00572_0004.jpg"/></fig></sec><sec id="sec3.3"><title>Stability of [<sup>67</sup>Ga] <italic toggle="yes">In Vitro</italic>
</title><p>
<italic toggle="yes">In vitro</italic> stability analysis of [<sup>67</sup>Ga]<bold>6</bold> in murine plasma at 37 &#176;C demonstrated that [<sup>67</sup>Ga]<bold>6</bold> was considerably stable, with radiochemical purities
after 10 min and 1 h being of 95.7 &#177; 1.1% and 94.9 &#177; 0.4%,
respectively. These findings indicate that under physiological conditions,
[<sup>67</sup>Ga]<bold>6</bold> maintains its structure and could
enable the transportation of boron to bone metastasis sites as the
target tissue without substantial degradation.</p></sec><sec id="sec3.4"><title>Biodistribution of [<sup>67</sup>Ga]<bold>6</bold> in Normal
Mice</title><p>The biodistribution of [<sup>67</sup>Ga]<bold>6</bold> in normal mice is presented in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>. [<sup>67</sup>Ga]<bold>6</bold> exhibited
high accumulation in bone and minimal accumulation in nontarget tissues,
besides kidneys, which are involved in excretion. Although the bone
accumulation of [<sup>67</sup>Ga]<bold>6</bold> was slightly lower
than that of [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub> and [<sup>67</sup>Ga]&#173;Ga-DOTA-d<sub>11</sub> (as observed in our previous studies<named-content content-type="bibref-group">
<xref rid="ref21" ref-type="bibr"/>,<xref rid="ref22" ref-type="bibr"/>
</named-content>), the overall biodistribution pattern was similar. Notably, [<sup>67</sup>Ga]<bold>6</bold> exhibited greater bone accumulation than
previously reported hybrid compounds such as [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-c&#173;(RGDfK) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>a), [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-TATE (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>b), and [<sup>67</sup>Ga]&#173;Ga-DOTA-D<sub>11</sub>-PSMA617 (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>c).<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>,<xref rid="ref25" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/>
</named-content> In these hybrids, the tumor-targeting moieties, such as the RGD
peptide, octreotide analog, and PSMA ligand, may hinder binding to
hydroxyapatite, as the D<sub>11</sub> component may be less accessible
owing to its position between the Ga-DOTA complex and the tumor-targeting
units. In comparison, the branched structure of [<sup>67</sup>Ga]<bold>6</bold> facilitates better access of D<sub>11</sub> to hydroxyapatite,
decreasing potential steric hindrance.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Biodistribution at 10
min, 1 h, and 3 h postinjection of [<sup>67</sup>Ga]<bold>6</bold> in normal mice. S. Intestine and L. Intestine
mean small intestine and large intestine, respectively. *Expressed
as %ID.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="mp5c00572_0005.jpg"/></fig></sec><sec id="sec3.5"><title>Analysis of Urine Samples</title><p>The typical chromatogram
of the urine sample of normal mice after injection of [<sup>67</sup>Ga]<bold>6</bold> is presented in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00572/suppl_file/mp5c00572_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>. Although hydrophilic metabolites were observed in the urine samples,
it was assumed that [<sup>67</sup>Ga]<bold>6</bold> was not metabolized
in the blood immediately after injection because [<sup>67</sup>Ga]<bold>6</bold> was stable in murine plasma <italic toggle="yes">in vitro</italic> and
that boron was delivered to the bone after injection of DOTA-K&#173;(&#949;-<italic toggle="yes">closo</italic>-dodecaborate)&#173;D<sub>11</sub> (<bold>5</bold>). In a
previous study, the ratio of the intact complex in the urine samples
after injection of [<sup>67</sup>Ga]&#173;Ga-DOTA-(<sc>d</sc>-Asp)<sub>14</sub> (85.8% &#177; 17.4%) was significantly higher than that of [<sup>67</sup>Ga]&#173;Ga-DOTA-(<sc>l</sc>-Asp)<sub>14</sub> (55.0% &#177; 13.9%).<xref rid="ref22" ref-type="bibr"/> However, the difference barely affected their
bone accumulation.</p></sec><sec id="sec3.6"><title>Biodistribution of <bold>5</bold> via ICP-OES in Normal Mice</title><p>
<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref> presents
a comparison of the biodistribution of <bold>5</bold> and [<sup>67</sup>Ga]<bold>6</bold> at 1 h postinjection in normal mice. Data, expressed
as %ID/g of <bold>5</bold> and [<sup>67</sup>Ga]<bold>6</bold> in
each tissue, were calculated using the boron concentration determined
via ICP-OES and the radioactivity of <sup>67</sup>Ga was measured
using a &#947;-counter, respectively.</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Biodistribution of [<sup>67</sup>Ga]<bold>6</bold> and <bold>5</bold> in normal mice at 1
h postinjection. Data were calculated using
boron concentration determined by ICP-OES and radioactivity of <sup>67</sup>Ga measured by a &#947;-counter, respectively. S. Intestine
and L. Intestine mean small intestine and large intestine, respectively.
*Expressed as %ID. <sup>#</sup>
<italic toggle="yes">p</italic> &lt; 0.001 vs [<sup>67</sup>Ga]<bold>6</bold>.</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="mp5c00572_0006.jpg"/></fig><p>Initially, we planned to compare the boron distribution
of <bold>6</bold> with the radioactivity distribution of [<sup>67</sup>Ga]<bold>6</bold> in each tissue. However, because of the challenges
in synthesizing
a sufficient quantity of <bold>6</bold> for this study, we evaluated <bold>5</bold>, a precursor lacking gallium coordination with DOTA, as
an alternative. In our previous study, we compared the biodistribution
profiles of Ga-DOTA-conjugated RGD peptide ([<sup>67</sup>Ga]&#173;Ga-DOTA-c&#173;[RGDf&#173;(4-I)&#173;K])
and DOTA-conjugated RGD peptide (DOTA-[<sup>125</sup>I]&#173;c&#173;[RGDf&#173;(4-I)&#173;K])<xref rid="ref34" ref-type="bibr"/> and found them to be similar irrespective of
Ga coordination. Based on these results, we hypothesized that the
biodistribution of <bold>5</bold> would be similar to that of <bold>6</bold>, with only minimal differences.</p><p>The aim of this study
was to develop theranostic compounds that
combine BNCT and PET imaging. A PET probe labeled with <sup>68</sup>Ga, which serves as an alternative to the <sup>67</sup>Ga-labeled
compound used for SPECT in this study, is expected to function as
a companion diagnostic agent for a BNCT drug. In other words, it is
crucial that [<sup>67</sup>Ga]<bold>6</bold> and <bold>6</bold> exhibit
equivalent pharmacokinetics <italic toggle="yes">in vivo</italic>. Comparison of
the pharmacokinetics of BNCT drugs and PET probes involves two key
considerations. First, while boron (<sup>10</sup>B) kinetics is important
in BNCT, the kinetics of the radioisotope is visualized in PET. Although
the chemical structures are identical and equivalent pharmacokinetics
are anticipated, discrepancies may arise if the complex is unstable&#58872;leading
to <italic toggle="yes">in vivo</italic> release of the radiometal&#58872;or if
the metabolites of the boron-containing portion are different from
those of the radioisotope-containing portion. In such cases, the pharmacokinetics
would not be equivalent. The second consideration is that the doses
of BNCT drugs and PET probes are substantially different. PET probes
are typically administered in tracer doses, which are considerably
small, while BNCT agents (e.g., [<sup>10</sup>B]&#173;boronophenylalanine
(BPA)) are administered in high doses as a high boron concentration
is required at the target lesion site. This difference could lead
to variations in pharmacokinetics and accumulation at the target site
because high doses may cause saturation of certain targets, such as
receptors. However, the target in this study is bone, specifically
the hydroxyapatite at bone metastasis sites, which possesses a large
binding capacity and does not get easily saturated. Therefore, even
at higher doses, the accumulation rate of the BNCT compound at the
lesion site is expected to be maintained. Indeed, the bone accumulation
and overall biodistribution of [<sup>67</sup>Ga]<bold>6</bold> and <bold>5</bold> were generally equivalent, indicating that [<sup>67/68</sup>Ga]<bold>6</bold> could serve as a companion diagnostic agent for <bold>5</bold> or <bold>6</bold> in BNCT. However, whether the observed
differences in intestinal accumulation result from the variations
in stoichiometry or subtle chemical differences remains to be determined.
However, when (Asp)<sub>11</sub> (515 &#956;g or 2.06 mg per mouse)
was administered in excessive amounts instead of <bold>6</bold> immediately
before the injection of [<sup>67</sup>Ga]<bold>6</bold>, the accumulation
of [<sup>67</sup>Ga]<bold>6</bold> in the bone decreased in (Asp)<sub>11</sub> dose-dependent manner (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00572/suppl_file/mp5c00572_si_001.pdf" ext-link-type="uri">Figure S3 and Table S3</ext-link>). The results are attributed to the greater affinity
of (Asp)<sub>11</sub> for hydroxyapatite compared with that of [<sup>67</sup>Ga]<bold>6</bold>, probably due to steric hindrance. If molar
equivalents of <bold>6</bold> to (Asp)<sub>11</sub> (515 &#956;g
or 2.06 mg) were administered and if <bold>6</bold> has the same affinity
for bone as (Asp)<sub>11</sub>, 2.00 and 4.50 ppm would accumulate
in bone, respectively, as per calculations. These values are lower
than the accumulation level (&gt;20 ppm in tumors) generally required
for effective BNCT.<xref rid="ref36" ref-type="bibr"/> However, the values
of 2.00 and 4.50 ppm are likely to be underestimations because the
affinity of (Asp)<sub>11</sub> for bone is expected to be higher than
that of <bold>6</bold>. Moreover, these values represent the average
accumulation in the normal femur, whereas bone metastasis sites as
the target generally exhibit higher accumulation of bone-seeking agents
than normal bone. Thus, <bold>6</bold> may be sufficient for clinical
application.</p></sec><sec id="sec3.7"><title>SPECT Imaging in Normal Mice</title><p>
<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref> shows a SPECT image acquired 3 h postinjection
of [<sup>67</sup>Ga]<bold>6</bold>. [<sup>67</sup>Ga]<bold>6</bold> demonstrated high accumulation in bone, particularly in the joint
regions, while exhibiting minimal uptake in nontarget tissues. Radioactivity
was also observed in the bladder, indicating that [<sup>67</sup>Ga]<bold>6</bold> is primarily excreted through the renal&#8211;bladder&#8211;urinary
pathway.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>A representative coronal maximal intensity projection (MIP) SPECT/CT
fusion image at 3 h postinjection of [<sup>67</sup>Ga]<bold>6</bold>.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="mp5c00572_0007.jpg"/></fig><p>The pronounced bone uptake of [<sup>67</sup>Ga]<bold>6</bold> is
attributable to its high affinity for hydroxyapatite. Similar to other
hydroxyapatite-targeted, bone-seeking radiopharmaceuticals, [<sup>67</sup>Ga]<bold>6</bold> is expected to accumulate preferentially
at sites of active bone remodeling, particularly those with elevated
osteoblastic activity.<xref rid="ref10" ref-type="bibr"/> The knee joint
in mice is known to exhibit elevated osteoblastic activity, likely
accounting for the substantial accumulation of [<sup>67</sup>Ga]<bold>6</bold> observed in this region. In our previous study, [<sup>186</sup>Re]&#173;Re-MAG3-conjugated bisphosphonate, which possesses high affinity
for hydroxyapatite, demonstrated high uptake in knee joints and a
bone metastasis site of a rat model.<xref rid="ref16" ref-type="bibr"/> These
findings collectively indicate that [<sup>67/68</sup>Ga]<bold>6</bold> may serve as a promising candidate for targeting osteoblastic bone
metastases, and as a noninvasive imaging tool for evaluating the distribution
and accumulation of its therapeutic counterpart, namely, [<sup>10</sup>B]<bold>6</bold>, for use in BNCT.</p><p>A recent study demonstrated
the therapeutic efficacy of BNCT using
[<sup>10</sup>B]&#173;BPA in a mouse model of metastatic spinal tumors.<xref rid="ref37" ref-type="bibr"/> In this study, the BPA-BNCT group showed significantly
prolonged survival compared with both untreated and neutron-only groups
(vs untreated, <italic toggle="yes">p</italic> = 0.0015; vs neutron-only, <italic toggle="yes">p</italic> = 0.0104, log-rank test), highlighting the therapeutic
potential of targeted BNCT for metastatic lesions. BPA is known to
selectively accumulate in tumor cells via the L-type amino acid transporter
1 (LAT1),<xref rid="ref38" ref-type="bibr"/> while <bold>6</bold> targets
hydroxyapatite, a major component of the bone matrix. The lack of
interaction between these two independent and noncompetitive mechanisms
supports the feasibility of a dual-agent BNCT strategy&#58872;wherein
BPA and <bold>6</bold> deliver boron to complementary targets within
the tumor microenvironment, namely tumor cells and osteoblastic lesions
at bone metastasis sites. An appropriate bone metastasis model is
currently under development to validate this hypothesis, and it will
be used in our future studies.</p></sec></sec><sec id="sec4"><title>Conclusion</title><p>In this study, we successfully designed
and synthesized [<sup>nat/67</sup>Ga]<bold>6</bold>, a novel theranostic
probe that integrates BNCT
with nuclear medicine imaging for the treatment of bone metastases.
Biodistribution experiments and SPECT imaging revealed that [<sup>67</sup>Ga]<bold>6</bold> exhibited high accumulation in bone tissue,
particularly in the knee joints, with minimal uptake in nontarget
organs. Moreover, the biodistribution pattern of [<sup>67</sup>Ga]<bold>6</bold> closely resembled that of <bold>5</bold>, the precursor
lacking gallium coordination of <bold>6</bold>. These findings indicate
that [<sup>nat/67/68</sup>Ga]<bold>6</bold> holds substantial potential
as an effective theranostic agent for the diagnosis and treatment
of bone metastases.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="mp5c00572_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>This work was partially funded by the Japan Society
for the Promotion of Science through Grants-in-Aid for Scientific
Research (21H02867), The NOVARTIS Foundation (Japan) for the Promotion
of Science, Kobayashi Foundation for Cancer Research, and The Naito
Foundation.</p></ack><notes id="notes2" notes-type="si"><p>The Supporting Information is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00572?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00572</ext-link>.<list list-type="simple" id="silist"><list-item><p>A HPLC chromatogram of <bold>5</bold>, <italic toggle="yes">in vitro</italic> stability of [<sup>67</sup>Ga]<bold>6</bold> in murine plasma, analysis
of [<sup>67</sup>Ga]<bold>6</bold> in urine, detailed biodistribution
data, <sup>1</sup>H NMR spectrum of <bold>1</bold>, and MS spectra
of <bold>3</bold>-<bold>6</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00572/suppl_file/mp5c00572_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes1" notes-type="author-contributions"><label>#</label><p>K.T. and Y.A.
contributed equally to this work.</p></notes><notes id="notes3" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><article-title>Boron neutron
capture therapy (BNCT): a unique role in radiotherapy with a view
to entering the accelerator-based BNCT era</article-title><source>Int. J. Clin. Oncol.</source><year>2020</year><volume>25</volume><issue>1</issue><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s10147-019-01480-4</pub-id><pub-id pub-id-type="pmid">31168726</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><article-title>The basis and advances
in clinical application of boron neutron capture therapy</article-title><source>Radiat. Oncol.</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>216</fpage><pub-id pub-id-type="doi">10.1186/s13014-021-01939-7</pub-id><pub-id pub-id-type="pmid">34743756</pub-id><pub-id pub-id-type="pmcid">PMC8573925</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Coderre</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>G. M.</given-names></name><article-title>The radiation biology
of boron neutron capture therapy</article-title><source>Radiat. Res.</source><year>1999</year><volume>151</volume><issue>1</issue><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.2307/3579742</pub-id><pub-id pub-id-type="pmid">9973079</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Nishimura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kashiwagi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukuo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Enomoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>H.</given-names></name><article-title>Efficient
neutron capture therapy of glioblastoma with pteroyl-closo-dodecaborate-conjugated
4-(p-iodophenyl)&#173;butyric acid (PBC-IP)</article-title><source>J. Controlled
Release</source><year>2023</year><volume>360</volume><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.06.022</pub-id><pub-id pub-id-type="pmid">37356755</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Cook</surname><given-names>G. J. R.</given-names></name><name name-style="western"><surname>Thorpe</surname><given-names>M. P.</given-names></name><article-title>Bone Metastases</article-title><source>Cancer J.</source><year>2024</year><volume>30</volume><issue>3</issue><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1097/PPO.0000000000000717</pub-id><pub-id pub-id-type="pmid">38753755</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Mahajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gavane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandit-Taskar</surname><given-names>N.</given-names></name><article-title>Targeted Radiopharmaceutical
Therapy
for Bone Metastases</article-title><source>Semin Nucl. Med.</source><year>2024</year><volume>54</volume><issue>4</issue><fpage>497</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2024.05.006</pub-id><pub-id pub-id-type="pmid">38937221</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Cook</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Shay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>C. C.</given-names></name><article-title>Integrating new
discoveries into the &#8243;vicious cycle&#8243; paradigm of prostate
to bone metastases</article-title><source>Cancer Metastasis Rev.</source><year>2014</year><volume>33</volume><issue>2</issue><fpage>511</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1007/s10555-014-9494-4</pub-id><pub-id pub-id-type="pmid">24414228</pub-id><pub-id pub-id-type="pmcid">PMC4096318</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Tsukamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kido</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Facchini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mavrogenis</surname><given-names>A. F.</given-names></name><article-title>Current
Overview of Treatment for
Metastatic Bone Disease</article-title><source>Curr. Oncol</source><year>2021</year><volume>28</volume><issue>5</issue><fpage>3347</fpage><lpage>3372</lpage><pub-id pub-id-type="doi">10.3390/curroncol28050290</pub-id><pub-id pub-id-type="pmid">34590591</pub-id><pub-id pub-id-type="pmcid">PMC8482272</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><article-title>State-of-the-art of minimally invasive treatments of bone metastases</article-title><source>Journal of Bone Oncology</source><year>2022</year><volume>34</volume><elocation-id>100425</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbo.2022.100425</pub-id><pub-id pub-id-type="pmid">35391944</pub-id><pub-id pub-id-type="pmcid">PMC8980625</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>A.</given-names></name><article-title>Well-designed bone-seeking
radiolabeled compounds for
diagnosis and therapy of bone metastases</article-title><source>BioMed
Res. Int.</source><year>2015</year><volume>2015</volume><elocation-id>676053</elocation-id><pub-id pub-id-type="doi">10.1155/2015/676053</pub-id><pub-id pub-id-type="pmid">26075256</pub-id><pub-id pub-id-type="pmcid">PMC4446473</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Washiyama</surname><given-names>K.</given-names></name><article-title>Bone target
radiotracers for palliative therapy of
bone metastases</article-title><source>Curr. Med. Chem.</source><year>2012</year><volume>19</volume><issue>20</issue><fpage>3290</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.2174/092986712801215865</pub-id><pub-id pub-id-type="pmid">22664247</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Nilsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cislo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sartor</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vogelzang</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>J.
M.</given-names></name><name name-style="western"><surname>Reuning-Scherer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>C.</given-names></name><article-title>Patient-reported quality-of-life
analysis of radium-223 dichloride from the phase III ALSYMPCA study</article-title><source>Ann. Oncol</source><year>2016</year><volume>27</volume><issue>5</issue><fpage>868</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw065</pub-id><pub-id pub-id-type="pmid">26912557</pub-id><pub-id pub-id-type="pmcid">PMC4843190</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kanbara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Odani</surname><given-names>A.</given-names></name><article-title>Preparation and evaluation of a radiogallium
complex-conjugated bisphosphonate as a bone scintigraphy agent</article-title><source>Nucl. Med. Biol.</source><year>2011</year><volume>38</volume><issue>5</issue><fpage>631</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2010.12.004</pub-id><pub-id pub-id-type="pmid">21718937</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takamura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hanaoka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saji</surname><given-names>H.</given-names></name><article-title>Usefulness
of competitive inhibitors of protein binding for improving the pharmacokinetics
of <sup>186</sup>Re-MAG3-conjugated bisphosphonate (<sup>186</sup>Re-MAG3-HBP), an agent for treatment of painful bone metastases</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2009</year><volume>36</volume><issue>1</issue><fpage>115</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s00259-008-0925-8</pub-id><pub-id pub-id-type="pmid">18709369</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Washiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saji</surname><given-names>H.</given-names></name><article-title>Development
of [<sup>90</sup>Y]&#173;DOTA-conjugated bisphosphonate for
treatment of painful bone metastases</article-title><source>Nucl.
Med. Biol.</source><year>2009</year><volume>36</volume><issue>2</issue><fpage>129</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2008.11.007</pub-id><pub-id pub-id-type="pmid">19217524</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saji</surname><given-names>H.</given-names></name><article-title>Therapeutic effects of a <sup>186</sup>Re-complex-conjugated bisphosphonate for the palliation of metastatic
bone pain in an animal model</article-title><source>J. Nucl. Med.</source><year>2007</year><volume>48</volume><issue>1</issue><fpage>122</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">17204708</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ono</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saji</surname><given-names>H.</given-names></name><article-title>Development
of a novel <sup>99m</sup>Tc-chelate-conjugated bisphosphonate with
high affinity for bone as a bone scintigraphic agent</article-title><source>J. Nucl. Med.</source><year>2006</year><volume>47</volume><issue>12</issue><fpage>2042</fpage><lpage>2047</lpage><pub-id pub-id-type="pmid">17138748</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Otaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Magata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saji</surname><given-names>H.</given-names></name><article-title>Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives
for bone pain palliation</article-title><source>Nucl. Med. Biol.</source><year>2006</year><volume>33</volume><issue>4</issue><fpage>513</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2006.03.006</pub-id><pub-id pub-id-type="pmid">16720243</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ono</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hanaoka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ishino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saji</surname><given-names>H.</given-names></name><article-title>Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate
for the palliation of metastatic bone pain based on the concept of
bifunctional radiopharmaceuticals</article-title><source>Bioconjug
Chem.</source><year>2005</year><volume>16</volume><issue>4</issue><fpage>751</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1021/bc040249w</pub-id><pub-id pub-id-type="pmid">16029015</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Uehara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z. L.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akizawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arano</surname><given-names>Y.</given-names></name><article-title>Assessment of 186Re chelate-conjugated
bisphosphonate for the development of new radiopharmaceuticals for
bones</article-title><source>Nucl. Med. Biol.</source><year>2007</year><volume>34</volume><issue>1</issue><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2006.10.001</pub-id><pub-id pub-id-type="pmid">17210464</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Odani</surname><given-names>A.</given-names></name><article-title>Development
of novel radiogallium-labeled
bone imaging agents using oligo-aspartic acid peptides as carriers</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>12</issue><elocation-id>e84335</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0084335</pub-id><pub-id pub-id-type="pmid">24391942</pub-id><pub-id pub-id-type="pmcid">PMC3877283</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kozaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Odani</surname><given-names>A.</given-names></name><article-title>Evaluation
of Ga-DOTA-(D-Asp)<sub>n</sub> as bone imaging agents: D-aspartic
acid peptides as carriers to bone</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>13971</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-14149-7</pub-id><pub-id pub-id-type="pmid">29070853</pub-id><pub-id pub-id-type="pmcid">PMC5656653</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Munekane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuchigami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Echigo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wakabayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><article-title>Differences in the
Renal Accumulation of Radiogallium-Labeled (Glu)<sub>14</sub> Peptides
Containing Different Optical Isomers of Glutamic Acid</article-title><source>Molecules</source><year>2024</year><volume>29</volume><issue>17</issue><fpage>3993</fpage><pub-id pub-id-type="doi">10.3390/molecules29173993</pub-id><pub-id pub-id-type="pmid">39274840</pub-id><pub-id pub-id-type="pmcid">PMC11396517</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Effendi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fuchigami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Munekane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wakabayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><article-title>Synthesis and Evaluation
of Radiogallium Labeled Bone-Imaging Probes Using Oligo-gamma-Carboxy
Glutamic Acid Peptides as Carriers to Bone</article-title><source>Mol. Pharmaceutics</source><year>2024</year><volume>21</volume><issue>5</issue><fpage>2375</fpage><lpage>2382</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c01156</pub-id><pub-id pub-id-type="pmid">38573777</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yokokawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Odani</surname><given-names>A.</given-names></name><article-title>Radiogallium Complex-Conjugated Bifunctional
Peptides for Detecting Primary Cancer and Bone Metastases Simultaneously</article-title><source>Bioconjug Chem.</source><year>2015</year><volume>26</volume><issue>8</issue><fpage>1561</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00186</pub-id><pub-id pub-id-type="pmid">26087328</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Ishizaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hanaoka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Odani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><article-title>Fundamental
study of radiogallium-labeled
aspartic acid peptides introducing octreotate derivatives</article-title><source>Ann. Nucl. Med.</source><year>2019</year><volume>33</volume><issue>4</issue><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1007/s12149-018-01326-5</pub-id><pub-id pub-id-type="pmid">30604401</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Hirata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fuchigami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Munekane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><article-title>Synthesis
and evaluation of a multifunctional probe with a high affinity for
prostate-specific membrane antigen (PSMA) and bone</article-title><source>Nucl. Med. Biol.</source><year>2022</year><volume>114&#8211;115</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2022.08.004</pub-id><pub-id pub-id-type="pmid">36088875</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Imai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ematsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fuchigami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Munekane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><article-title>RGD Peptide-Conjugated
Dodecaborate with the Ga-DOTA Complex: A Preliminary Study for the
Development of Theranostic Agents for Boron Neutron Capture Therapy
and Its Companion Diagnostics</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><issue>24</issue><fpage>16741</fpage><lpage>16753</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01586</pub-id><pub-id pub-id-type="pmid">36512639</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Ben
Azzouna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benali</surname><given-names>K.</given-names></name><name name-style="western"><surname>Al-Shoukr</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>W.</given-names></name><name name-style="western"><surname>Karoyan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rouzet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Le Guludec</surname><given-names>D.</given-names></name><article-title>Synthesis,
gallium labelling and characterization of P04087, a functionalized
phosphatidylserine-binding peptide</article-title><source>EJNMMI Radiopharmacy
Chem.</source><year>2017</year><volume>2</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s41181-016-0021-5</pub-id><pub-id pub-id-type="pmcid">PMC5835976</pub-id><pub-id pub-id-type="pmid">29527564</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Echigo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Munekane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuchigami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Washiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wakabayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><article-title>Optimizing the pharmacokinetics
of
an <sup>211</sup>At-labeled RGD peptide with an albumin-binding moiety
via the administration of an albumin-binding inhibitor</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2024</year><volume>51</volume><issue>9</issue><fpage>2663</fpage><lpage>2671</lpage><pub-id pub-id-type="doi">10.1007/s00259-024-06695-w</pub-id><pub-id pub-id-type="pmid">38570359</pub-id><pub-id pub-id-type="pmcid">PMC11224111</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Jagadish</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brickert-Albrecht</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Nichol</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Mash</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Raghunand</surname><given-names>N.</given-names></name><article-title>On the Synthesis
of 1,4,7-Tris&#173;(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane</article-title><source>Tetrahedron Lett.</source><year>2011</year><volume>52</volume><issue>17</issue><fpage>2058</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2010.10.074</pub-id><pub-id pub-id-type="pmid">21516221</pub-id><pub-id pub-id-type="pmcid">PMC3079211</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kanbara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kozaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Odani</surname><given-names>A.</given-names></name><article-title>Development and evaluation
of a radiobromine-labeled sigma ligand
for tumor imaging</article-title><source>Nucl. Med. Biol.</source><year>2013</year><volume>40</volume><issue>4</issue><fpage>445</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2013.02.008</pub-id><pub-id pub-id-type="pmid">23528561</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Effendi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><article-title>Development
of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor
Receptor beta (PDGFRbeta) Imaging: Influence of Different Linkers</article-title><source>Molecules</source><year>2020</year><volume>26</volume><issue>1</issue><fpage>41</fpage><pub-id pub-id-type="doi">10.3390/molecules26010041</pub-id><pub-id pub-id-type="pmid">33374773</pub-id><pub-id pub-id-type="pmcid">PMC7795354</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Echigo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mishiro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Washiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kinuya</surname><given-names>S.</given-names></name><article-title>
<sup>68</sup>Ga- and <sup>211</sup>At-Labeled RGD Peptides for Radiotheranostics
with Multiradionuclides</article-title><source>Mol. Pharmaceutics</source><year>2021</year><volume>18</volume><issue>9</issue><fpage>3553</fpage><lpage>3562</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00460</pub-id><pub-id pub-id-type="pmid">34403257</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Bibi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Mushtaq</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.-A.</given-names></name><article-title>Development
of Structurally Identical Therapeutic and Diagnostic Agents for Image-Guided
Boron Neutron Capture Therapy: c&#173;(RGD-BPA-K) Peptide with <sup>125</sup>I/<sup>nat</sup>I Albumin-Binding Moiety</article-title><source>Mol.
Pharmaceutics</source><year>2025</year><volume>22</volume><issue>6</issue><fpage>3423</fpage><lpage>3432</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5c00291</pub-id><pub-id pub-id-type="pmid">40307189</pub-id></element-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Imlimthan</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western"><surname>Bahrami</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Pehkonen</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Centanni</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Montaser</surname>, <given-names>A. B.</given-names></string-name>; <string-name name-style="western"><surname>Vara</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Matovic</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Liljenback</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Auchynnikava</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Huttunen</surname>, <given-names>K. M.</given-names></string-name>; <string-name name-style="western"><surname>Roivainen</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Airaksinen</surname>, <given-names>A. J.</given-names></string-name>; <string-name name-style="western"><surname>Ekholm</surname>, <given-names>F. S.</given-names></string-name>; <string-name name-style="western"><surname>Monni</surname>, <given-names>O.</given-names></string-name>; <string-name name-style="western"><surname>Rautio</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Sarparanta</surname>, <given-names>M.</given-names></string-name></person-group><article-title>Biological
evaluation
of a glucose-based boron carrier as a potential agent for boron neutron
capture therapy</article-title>. <source>Int. J. Cancer</source><year>2025</year>.<pub-id pub-id-type="doi">10.1002/ijc.70054</pub-id><pub-id pub-id-type="pmid">40699179</pub-id></mixed-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Fujikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsujino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kashiwagi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yagi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hiramatsu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nonoguchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wanibuchi</surname><given-names>M.</given-names></name><article-title>Boron neutron
capture therapy delays the decline in neurological function in a mouse
model of metastatic spinal tumors</article-title><source>Cancer Sci.</source><year>2024</year><volume>115</volume><issue>8</issue><fpage>2774</fpage><lpage>2785</lpage><pub-id pub-id-type="doi">10.1111/cas.16245</pub-id><pub-id pub-id-type="pmid">38860412</pub-id><pub-id pub-id-type="pmcid">PMC11309935</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Detta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cruickshank</surname><given-names>G. S.</given-names></name><article-title>L-amino
acid transporter-1 and boronophenylalanine-based
boron neutron capture therapy of human brain tumors</article-title><source>Cancer Res.</source><year>2009</year><volume>69</volume><issue>5</issue><fpage>2126</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2345</pub-id><pub-id pub-id-type="pmid">19244126</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>